(Q37144253)

English

Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus

scientific article published on April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus (English)

1 reference

Europe PubMed Central

18 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

Edward J. Mills

2

object named as

Edward Mills

1 reference

Europe PubMed Central

18 August 2017

author name string

Cecilia T Costiniuk

1

1 reference

Europe PubMed Central

18 August 2017

Curtis L Cooper

3

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

1 April 2008

1 reference

Europe PubMed Central

18 August 2017

Canadian Journal of Gastroenterology & Hepatology

1 reference

Europe PubMed Central

18 August 2017

22

1 reference

Europe PubMed Central

18 August 2017

4

1 reference

Europe PubMed Central

18 August 2017

376-380

1 reference

Europe PubMed Central

18 August 2017

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

1 January 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Cannabis use improves retention and virological outcomes in patients treated for hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Side effects of medical therapy for chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

The therapeutic potential of cannabis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Cannabis and the brain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Established and potential therapeutic applications of cannabinoids in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Potential interventions for HIV/AIDS wasting: an overview

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Molecular characterization of a peripheral receptor for cannabinoids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Recent clinical experience with dronabinol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

6 September 2017

Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

14 September 2017

Abuse potential of dronabinol (Marinol).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

27 June 2018

Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

27 June 2018

The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

27 June 2018

Dronabinol effects on weight in patients with HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

27 June 2018

Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

27 June 2018

The management of chronic viral hepatitis: A Canadian consensus conference 2004.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

3 September 2018

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

3 September 2018

Maximizing the benefits of antiviral therapy for HCV: the advantages of treating side effects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

3 September 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662895

3 September 2018

Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo

1 reference

https://pubmed.ncbi.nlm.nih.gov/18414712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of cellular mediated immunity in marihuana smokers

1 reference

https://pubmed.ncbi.nlm.nih.gov/18414712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genital warts do not respond to systemic recombinant interferon alfa-2a treatment during cannabis consumption

1 reference

https://pubmed.ncbi.nlm.nih.gov/18414712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Efficacy and Safety of Nabilone (A Synthetic Cannabinoid) in the Treatment of Anxiety

1 reference

https://pubmed.ncbi.nlm.nih.gov/18414712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2008/725702

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37144253&oldid=1797389739"